Oculis (NASDAQ:OCS) Trading Down 9.1% - Time to Sell?

Oculis Holding AG (NASDAQ:OCS - Get Free Report)'s share price was down 9.1% during trading on Monday . The stock traded as low as $14.04 and last traded at $14.09. Approximately 131,275 shares changed hands during trading, an increase of 74% from the average daily volume of 75,395 shares. The stock had previously closed at $15.50.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on OCS. Robert W. Baird upped their price target on shares of Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th. Chardan Capital restated a "buy" rating and issued a $28.00 target price on shares of Oculis in a research report on Thursday, March 13th. Finally, HC Wainwright lowered their price target on Oculis from $30.00 to $29.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th.

Oculis Stock Performance

The stock has a market cap of $731.34 million, a price-to-earnings ratio of -8.68 and a beta of 0.19. The company's 50-day simple moving average is $19.22 and its 200-day simple moving average is $17.82. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. Analysts predict that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of large investors have recently made changes to their positions in OCS. Citadel Advisors LLC acquired a new position in Oculis during the fourth quarter valued at $389,000. Bank of America Corp DE grew its stake in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after acquiring an additional 10,667 shares in the last quarter. Bellevue Group AG purchased a new position in Oculis during the 4th quarter valued at about $170,000. XTX Topco Ltd acquired a new position in shares of Oculis in the 4th quarter valued at about $225,000. Finally, Geode Capital Management LLC lifted its position in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 22.30% of the company's stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.